Mysthera Therapeutics has pioneered groundbreaking oral treatments for complex autoimmune diseases.
They focus on PIM kinases, which play a vital role in multiple immune cell types, like B and T cells, triggering excessive inflammation. Elevated PIM kinase levels may also contribute to the formation of tertiary lymphoid structures (TLS), linked to disease severity and progression.
The innovative approach uniquely targets the communication between these cells, disrupting the harmful formation of TLS associated with more severe disease cases.
Leveraging deep expertise in PIM kinase and immunology, Mysthera is taking a highly distinctive approach to combat complex autoimmune diseases, potentially bringing life-changing treatments to patients worldwide.
Despite recent advancements and new treatment options, autoimmune diseases continue to affect over 23 million people in the US alone, with significant unmet needs due to poor response rates and safety concerns associated with existing medications.
